Back to Search

Polatuzumab for Diffuse Large B-Cell Lymphoma

A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

Recruiting Observational Study
Diffuse Large B-Cell Lymphoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
1,000 (estimated)
Sponsor
Hoffmann-La Roche · Industry
Who this trial is looking for

This trial is looking for adults diagnosed with diffuse large B-cell lymphoma (DLBCL) to see how well polatuzumab works in real-world settings. Participants will be evaluated based on their health status and previous treatments.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with diffuse large B-cell lymphoma.
  • I am 80 years old or older, or younger but not healthy enough for standard treatment.
  • I have DLBCL but I'm not in the unfit/frail category.
  • I have relapsed or my disease did not respond to previous treatment.

You may not be able to join if

  • I am currently in or plan to join another clinical trial.
  • I have another reason that makes me unsuitable for this study, according to the doctor.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to assess the progression free survival (PFS) in the real-world settings of polatuzumab among Chinese diffuse large B cell lymphoma (DLBCL) participants.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Be diagnosed as DLBCL * Cohort 1: diagnosed as unfit/frail DLBCL. The unfit/frail is defined as aged 80 years or older, or younger than 80 years but with comorbidity and not tolerant to the standardized dose of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) …
Contacts

ML44616 https://forpatients.roche.com/

888-662-6728 (U.S. Only)

global-roche-genentech-trials@gene.com

CONTACT

NCT ID: NCT05954910 Source: ClinicalTrials.gov